

Press release

Successful completion of LIMFRA-study

Frankfurt/Main, Germany, 1 July 2009

Today LEUKOCARE announced the successful completion of the LIMFRA-Trial at the University Hospital of Frankfurt/Main, Germany.

In this study with 150 patients the medical device combination product “Leukocyte Inhibition Module” (LIM) developed by LEUKOCARE AG, Munich, Germany significantly reduced inflammation in patients undergoing cardiac surgery with heart-lung machine. The LIM contains immobilized antibodies that rapidly attenuate hyperactivated neutrophil granulocytes (a subset of white blood cells) within the blood stream. The LIMFRA study conducted by Prof. Dr. med. Anton Moritz, Director of the Department of Thoracic and Cardiovascular Surgery, showed that LIM could be easily incorporated into the circuit of the heart-lung machine, and proved to be safe and effective.

“Aberrant inflammation is a major problem in medicine. The results of the clinical trial and the achievement of the objectives show that the LIM technology is an enormous improvement for severely ill patients by preventing the dangerous hyperactivation of neutrophil granulocytes during critical clinical situations” stated Prof. Dr. Martin Scholz, CSO of LEUKOCARE. “Additionally, the proven functionality of the LIM demonstrated that our proprietary Stabilizing Postcoating technology protected the antibodies within the LIM during standard sterilization. LEUKOCARE is convinced that the Stabilizing Postcoating ought to be generally used for the production of any biologically functionalized medical devices in the future.”

Currently, LEUKOCARE is negotiating the out-licensing of the LIM technology and the Postcoating technology with different industrial companies.

About LEUKOCARE

LEUKOCARE is a product-focused, clinical-stage biotechnology company founded in 2001 and headquartered in Munich, Germany. LEUKOCARE is a

leading solution provider to biofunctionalize surfaces, primarily of medical devices, by its Stabilizing Postcoating technology, allowing the standard sterilization of proteins by e.g. irradiation or ethylene oxide.

By coupling, protecting and – if desirable - eluting biofunctional molecules (e.g. proteins, peptides, small molecules) LEUKOCARE can functionalize a wide variety of surfaces including implant surfaces, wound dressings, patches, stents, catheters, columns for ex-vivo blood treatment and others. These technologies are characterized by their modular versatility and biocompatibility.

LEUKOCARE utilizes its comprehensive biofunctional coating expertise in product-focused industry partnerships. The company offers its know-how in biofunctional coatings and product development to interested parties on a flexible basis ranging from service-based collaborations to co-development partnerships.

For further information please visit our homepage www.leukocare.com or contact us:

Julian Hergenröther

Business Development

Phone: +49 (0)89 780 16 65 – 13

Fax: +49 (0)89 780 16 65 – 11

Email: julian.hergenroether@leukocare.com